Core Viewpoint - The surge in Huajian Medical's stock price is driven by its announcement to apply for stablecoin issuance licenses in Hong Kong and the U.S., positioning itself as a pioneer in the medical technology sector for stablecoin issuance [2][3][4]. Group 1: Stock Performance - On July 21, Huajian Medical's stock opened significantly higher, peaking at a 58% increase, and closed up 32.88% at HKD 3.92 per share, with a market capitalization of HKD 6.356 billion [2]. - The company experienced a cumulative stock increase of 60% over two days, with trading volume exceeding HKD 50 million [2]. Group 2: Business Developments - On July 17, Huajian Medical announced the initiation of its stablecoin issuance license application process with relevant regulatory bodies in Hong Kong and the U.S. [2][3]. - The company’s U.S. subsidiary, IVDGROUPINC., has completed its registration and is now officially starting the stablecoin license application process [3]. Group 3: Market Reactions and Analysis - The market has shown mixed reactions to Huajian Medical's cross-industry initiatives, with some skepticism regarding its motives and the potential for "storytelling" [3]. - Analysts suggest that the company's approach addresses long-standing issues in the innovative drug sector, such as low liquidity and long financing cycles, by creating a Real World Asset (RWA) exchange focused on medical innovation [3][4]. Group 4: Regulatory Environment - Recent legislative developments in Hong Kong and the U.S. provide a favorable regulatory framework for stablecoin operations, enhancing Huajian Medical's strategic positioning [4]. - The Hong Kong Legislative Council's approval of the Stablecoin Bill marks a significant regulatory milestone, establishing a comprehensive framework for stablecoins and attracting Web3 projects to the region [4]. Group 5: Future Outlook - Market sentiment indicates confidence in the "innovative drug + stablecoin" integration, with expectations that Huajian Medical's RWA ecosystem could reshape valuation logic in the medical innovation sector [5]. - The potential for the company's stock to continue rising remains a point of interest for investors as it navigates the stablecoin landscape [5].

Core Viewpoint - As of July 21, 200 stocks reached their 52-week highs, with notable performers including Dongfang Electric (681.62%), Huaxin Cement (84.42%), and Aoyuan Group Equity (80.00%) [1][2]. Summary by Category 52-Week High Performers - Dongfang Electric (01072) closed at 24.650, with a peak price of 119.900, achieving a high rate of 681.62% [2]. - Huaxin Cement (06655) closed at 18.600, with a peak price of 20.100, achieving a high rate of 84.42% [2]. - Aoyuan Group Equity (02905) closed at 0.350, with a peak price of 0.450, achieving a high rate of 80.00% [2]. - Other notable stocks include: - Zhong'an Holdings Group (08462) with a high rate of 71.05% [2]. - Huajian Medical (01931) with a high rate of 57.97% [2]. - Songjing Technology (01079) with a high rate of 44.76% [2]. Additional High Performers - China Pipe Industry (00380) reached a high rate of 43.67% [2]. - Tibet Water Resources (01115) achieved a high rate of 39.33% [2]. - China Energy Construction (03996) reached a high rate of 38.03% [2]. - Other stocks with notable high rates include: - Changsheng Group-B (06628) at 25.23% [2]. - Harbin Electric (01133) at 24.84% [2]. - Fangyuan Life Services (09978) at 22.11% [2].

Core Viewpoint - The stablecoin industry is transitioning from "concept exploration" to "compliance implementation," with a focus on regulatory clarity and the establishment of a full industry chain in the Hong Kong stock market, where nearly 20 stablecoin concept stocks are involved [1]. Group 1: Business Positioning - Hong Kong stablecoin concept stocks generally focus on cross-border payments and broad RWA applications, with a "breadth-first" business model [2]. - In contrast, Huajian Medical's IVDD stablecoin adopts a "depth-first" strategy, concentrating on high-barrier medical innovation assets, including gene therapies and targeted drugs [3]. Group 2: Technical Architecture - Most Hong Kong stablecoin concept stocks utilize a "public chain + smart contract" generic architecture [4]. - Huajian Medical's IVDD employs a "hybrid architecture + deep adaptation to medical scenarios," enhancing asset tokenization precision and efficiency [6][7]. Group 3: Compliance Pathways - Hong Kong stablecoin concept stocks exhibit a "license-driven" compliance approach, with companies like Guotai Junan International obtaining licenses to provide stablecoin trading services [8][9]. - Huajian Medical's IVDD follows a "license + ecosystem" dual-driven model, applying for a stablecoin license while building a medical data flow platform [10]. Group 4: Ecological Value - Most Hong Kong stablecoin concept stocks are positioned as "payment tools," focusing on facilitating transactions [11][12]. - Huajian Medical's IVDD aims to be a "medical industry innovator," enhancing asset liquidity and potentially transforming the medical asset value ecosystem [13]. Group 5: Future Outlook - The implementation of Hong Kong's Stablecoin Regulation and the advancement of the U.S. GENIUS Act will lead to differentiation among Hong Kong stablecoin concept stocks [14]. - Huajian Medical's IVDD, as a pioneer in medical RWA, is expected to replicate successful financing models and expand its asset management scale significantly [15][16].

Core Viewpoint - The company is actively constructing a Web3 exchange ecosystem centered around high-tech medical innovation assets, aiming to enhance liquidity, financing efficiency, and accessibility in the global medical innovation drug market [1][2]. Group 1: Strategic Developments - The company has established a wholly-owned subsidiary in New York, IVD GROUP INC., which will serve as the core operational entity for advancing the IVDNewCo Exchange strategy in the U.S. [1][2] - The subsidiary has officially initiated the application process for a stablecoin license with relevant U.S. regulatory bodies, demonstrating the company's commitment to global compliance and proactive strategy execution [2][3]. - The IVDNewCo Exchange ecosystem plan will be implemented in the U.S., including the creation of a tokenization platform for real-world assets based on medical innovation drug assets and establishing compliant financial infrastructure for the issuance, trading, and clearing of the IVDD stablecoin [2][3]. Group 2: Market Positioning - The company aims to become the first compliant trading platform focused on medical innovation drug RWA, leveraging its commercial network covering 1,674 tertiary hospitals in China and its capability to acquire quality NewCo assets globally [3]. - The strategic acceleration in the U.S. marks the transition of the company's "NewCo + RWA + stablecoin" strategy into a phase of large-scale implementation, positioning it to participate in the trillion-dollar compliant stablecoin market [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：1931） 自願性公告 美國穩定幣牌照申請及 IVDNewCo Exchange生態落地正式開啓 本 公 告 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 自 願 作 出。本 公 告 旨 在 進 一 步 更 新 本 公 司 於 二 零 二 五 年 七 月 十 七 日 發 布 之 自 願 性 公 告（「前次公告」）所 披 露 的 戰 略 舉 措 進 展，並 向 股 東 及 潛 在 投 資 者 提 供 本 集 團 業 務 發 展 之 資 料。除 非 文 義 另 有 所 指，否 則 本 公 告 所 用 詞 彙 與 前 次 公 告 所 界 定 者 ...

Core Viewpoint - The recent approval of the Stablecoin Bill by the Hong Kong Legislative Council aims to establish a licensing system for fiat-backed stablecoin issuers, enhancing regulatory clarity and support for the virtual asset ecosystem. Group 1: Regulatory Environment - The global regulatory stance is shifting, with the U.S. gradually loosening its pilot policies on stablecoins, allowing certain states to operate ahead of broader regulations. Hong Kong has also announced plans to regulate three categories of stablecoins, supporting and standardizing the virtual asset ecosystem [4]. - The regulatory landscape is evolving, with Hong Kong's Monetary Authority and U.S. regulators receiving stablecoin applications from Huajian Medical, positioning the company to capitalize on regulatory opportunities [3]. Group 2: Business Model and Growth Potential - The success of integrating stablecoin structures with real-world asset (RWA) medical assets will determine Huajian Medical's transition from a "medical service exporter" to a "medical fintech platform." If successful, it could become the first Hong Kong-listed company to achieve a true "medical RWA + Web3" closed loop [2]. - The dual licensing path is significant as it not only provides a channel for token issuance but also serves as a crucial bridge for global capital to enter the medical RWA market. This dual license can enhance multi-market payment connectivity and credibility [5]. Group 3: Strategic Partnerships - International partners are more inclined to engage with platforms that possess regulatory licenses. Huajian Medical is planning to introduce compliant structured financing tools and design different channels for U.S. and Hong Kong fund clients [6].

Group 1: Market Performance - The Hong Kong stock market indices collectively rebounded, with the Hang Seng Index rising by 1.33%, the Hang Seng China Enterprises Index increasing by 1.51%, and the Hang Seng Tech Index gaining 1.65% [1] - The SaaS sector saw significant gains, with companies like Huilyang Technology rising by 15.56%, Yika by 10.11%, and Kingdee International by 7.27% [1] - The stablecoin concept also surged, highlighted by Yaocai Securities rising by 16.93% and Huajian Medical increasing by 20.41% following the U.S. House of Representatives passing a bill to establish a legal framework for stablecoins [1] Group 2: Sector Performance - Gold and non-ferrous metal stocks experienced a broad increase, with Lingbao Gold rising by 6.24% and China Molybdenum by 3.96% as spot gold prices rose above $3340 per ounce [2] - Major financial sectors, including Chinese brokerage and insurance stocks, also saw gains, with Xingsheng International up by 7.41% and China Life by 5.13% [2] Group 3: Automotive and Related Sectors - The automotive sector, including lithium battery and Tesla-related stocks, showed strong performance, with Tianqi Lithium rising by 5.82% and NIO increasing by 4.62% [3] - Other consumer sectors such as film, tobacco, and food stocks also performed well, with companies like Simoer International rising by 4.99% [3] Group 4: Declining Sectors - Sectors such as cosmetics, aviation, and luxury goods saw declines, with China Eastern Airlines dropping by 2.72% [3] - Notably, Chuangmeng Tiandi experienced a significant drop of 30.12%, despite expectations of turning a profit in the first half of the year [3]

Core Viewpoint - As of July 18, 160 stocks reached their 52-week highs, with notable performances from China New Economy Investment (00080), Aoyuan Group Equity (02905), and Zhong An Holdings Group (08462) showing high growth rates of 288.89%, 55.28%, and 50.00% respectively [1][2]. Summary by Category 52-Week High Performers - China New Economy Investment (00080) closed at 0.440, with a peak price of 0.700, achieving a growth rate of 288.89% [2]. - Aoyuan Group Equity (02905) closed at 0.218, with a peak price of 0.250, achieving a growth rate of 55.28% [2]. - Zhong An Holdings Group (08462) closed at 0.221, with a peak price of 0.228, achieving a growth rate of 50.00% [2]. - Other notable performers include Hualian International (00969) with a growth rate of 40.13% and Zhongke Bio (01237) with a growth rate of 37.25% [2]. Additional High Performers - Wanma Holdings (06928) closed at 0.550 with a growth rate of 30.43% [2]. - Lepu Biopharma-B (02157) closed at 7.940 with a growth rate of 24.54% [2]. - Other stocks with significant growth include ZhiJianYueDong (06860) at 17.14% and China Jindian Group (08281) at 17.12% [2]. 52-Week Low Performers - The document also lists stocks that reached their 52-week lows, with XI Ernan CO-U (09311) showing a decline of 16.10% [6]. - Other notable declines include XI Ernan CO (07311) at -12.62% and Haotian International Construction Investment (01341) at -5.70% [6].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 本 公 司 董 事（「董 事」）會（「董事會」）欣 然 宣 布，本 公 司 正 積 極 推 進 一 項 具 有 里 程 碑 意 義 的 戰 略 舉 措，即 構 建 以 醫 療 創 新 藥 高 科 技 資 產 為 核 心 的「NewCo + RWA」Web3交 易 所 生 態（下 稱「本生態」），該 生 態 將 命 名 為「IVDNewCo Exchange」（下 稱「交易所」），並 配 套 發 行 專 有 穩 定 幣(IVDDollar)（「IVDD」）。 本 戰 略 旨 在 顛 覆 傳 統 醫 藥 行 業 發 展 規 則，通 過 整 合Web3技 術（包 括RWA真 實 世 界 資 產 代 幣 化、區 塊 鏈 交 易 及 穩 定 幣 機 制），提 升 全 球 醫 療 創 新 藥 資 產 的 ...

7月15日，截至港股收盘，恒生指数上涨1.6%，报24590.12点。华检医疗（01931.HK）收报2.28港元/ 股，上涨12.87%，成交量44.5万股，成交额97.76万港元，振幅11.88%。 最近一个月来，华检医疗累计跌幅10.62%，今年来累计涨幅12.22%，跑输恒生指数20.65%的涨幅。 财务数据显示，截至2024年12月31日，华检医疗实现营业总收入31.62亿元，同比增长2.4%；归母净利 润2.6亿元，同比增长9.35%；毛利率23.75%，资产负债率31.91%。 资料显示，华检医疗控股有限公司于2016年01月15日根据开曼群岛法注册成立,其主要业务为投资控 股。集团在中国香港设有三家子公司,威士达医疗有限公司、中华检验国际有限公司及艾维德(中国)有限 公司。三家子公司在中国大陆各设有子公司或分公司,在全国各主要城市设有办事处。公司拥有超700名 员工,主要从事研发、生产、销售体外诊断的医疗仪器及耗材,业务遍布中国及中国香港。从1993年创立 威士达医疗有限公司,公司专注体外诊断业务,经过二十多年的发展,公司现已成为中国领先的体外诊断业 务的专业公司,为中国检验界提供超值产品及服 ...